Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

    ... common grade 3-4 treatment-emergent adverse events were neutropenia (52%) and leukopenia (39%). Pharmacokinetic profiles were ...

    Research Article last updated 02/03/2017 - 10:05am.

  2. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is unresponsive to other therapies. ...

    Research Article last updated 07/09/2013 - 3:03pm.

  3. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... and 0.001, respectively). The incidences of grades 3-4 neutropenia , thrombocytopenia , leukopenia, anemia , deep ...

    Research Article last updated 11/28/2016 - 9:36am.

  4. Treatment of low-risk myelodysplastic syndromes

    ... good efficacy, but raised some safety concern. Although neutropenia is targeted symptomatically with growth factor ...

    Research Article last updated 01/26/2017 - 10:42am.

  5. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia

    ... been reported in a minority of patients with congenital neutropenia and aplastic anemia (AA). The bone marrow (BM) ...

    Research Article last updated 11/25/2014 - 9:57am.

  6. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.

    ... was considerable, mainly due to prolonged absolute neutropenia , which occurred regardless of pre-therapy blood counts and ...

    Research Article last updated 10/07/2014 - 8:33am.

  7. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

    ... was considerable, mainly due to prolonged absolute neutropenia , which occurred regardless of pre-therapy blood counts and ...

    Research Article last updated 09/24/2014 - 10:17am.

  8. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

    ... events >30% included diarrhea, fatigue, nausea, febrile neutropenia , and stomatitis. Results suggest modest activity in AML, ...

    Research Article last updated 08/04/2014 - 8:28am.

  9. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results ...

    Research Article last updated 05/22/2014 - 9:28am.

  10. Myelodysplastic syndromes: a challenging disease for patients and physicians

    ... the treatment carries a high risk of rapidly developing neutropenia and thrombocytopenia . Several promising drugs are ...

    Research Article last updated 07/31/2012 - 1:58pm.